Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 619, Issue 1-2, 2007, Pages 16-29

  Le Fevre, Anne Celine ^a,b   Boitier, Eric ^a   Marchandeau, Jean Pierre ^a   Sarasin, Alain ^b   Thybaud, Veronique ^a  

^a SANOFI   (France)

^b CNRS FRE2939   (France)

Author keywords

Anticancer drugs; Cell cycle; Classification; Gene expression; TK6 lymphoblastoid cell line

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CAMPTOTHECIN; CARMUSTINE; CISPLATIN; CYTARABINE; DAUNORUBICIN; DNA; ETOPOSIDE; FLUOROURACIL; HYDROXYUREA; LOMUSTINE; METHOTREXATE; PACLITAXEL; VINCRISTINE;

ARTICLE; CELL COUNT; CELL CYCLE; COMPUTER PROGRAM; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOTOXICITY; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; MARKER GENE; MEDICAL TECHNOLOGY; MICRONUCLEUS TEST; PREDICTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE; CELL SURVIVAL; GENE EXPRESSION PROFILING; HUMANS; MICRONUCLEUS TESTS; MODELS, BIOLOGICAL; MUTAGENS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; THYMIDINE KINASE;

EID: 34247128690     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2006.12.007     Document Type: Article

References (50)

1. Zembutsu H., Ohnishi Y., Tsunoda T., Furukawa Y., Katagiri T., Ueyama Y., Tamaoki N., Nomura T., Kitahara O., Yanagawa R., Hirata K., and Nakamura Y. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res. 62 (2002) 518-527
2. Los G., Yang F., Samimi G., Manorek G., Guerorguieva I.M., Howell S., van E.N., and Breaux J.K. Using mRNA expression profiling to determine anticancer drug efficacy. Cytometry 47 (2002) 66-71
3. Dan S., Tsunoda T., Kitahara O., Yanagawa R., Zembutsu H., Katagiri T., Yamazaki K., Nakamura Y., and Yamori T. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 62 (2002) 1139-1147
4. Kihara C., Tsunoda T., Tanaka T., Yamana H., Furukawa Y., Ono K., Kitahara O., Zembutsu H., Yanagawa R., Hirata K., Takagi T., and Nakamura Y. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res. 61 (2001) 6474-6479
5. Thieblemont C., Nasser V., Felman P., Leroy K., Gazzo S., Callet-Bauchu E., Loriod B., Granjeaud S., Gaulard P., Haioun C., Traverse-Glehen A., Baseggio L., Bertucci F., Birnbaum D., Magrangeas F., Minvielle S., vet-Loiseau H., Salles G., Coiffier B., Berger F., and Houlgatte R. Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood 103 (2004) 2727-2737
6. Aardema M.J., and MacGregor J.T. Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies. Mutat. Res. 499 (2002) 13-25
7. Oberemm A., Onyon L., and Gundert-Remy U. How can toxicogenomics inform risk assessment?. Toxicol. Appl. Pharmacol. 207 (2005) 592-598
8. Reynolds V.L. Applications of emerging technologies in toxicology and safety assessment. Int. J. Toxicol. 24 (2005) 135-137
9. Kirsch-Volders M., Aardema M., and Elhajouji A. Concepts of threshold in mutagenesis and carcinogenesis. Mutat. Res. 464 (2000) 3-11
10. Henderson L., Albertini S., and Aardema M. Thresholds in genotoxicity responses. Mutat. Res. 464 (2000) 123-128
11. Aubrecht J., and Caba E. Gene expression profile analysis: an emerging approach to investigate mechanisms of genotoxicity. Pharmacogenomics 6 (2005) 419-428
12. Jeffrey A.M., and Williams G.M. Risk assessment of DNA reactive carcinogens in food. Toxicol. Appl. Pharmacol. 207 (2005) 628-635
13. Dickinson D.A., Warnes G.R., Quievryn G., Messer J., Zhitkovich A., Rubitski E., and Aubrecht J. Differentiation of DNA reactive and non-reactive genotoxic mechanisms using gene expression profile analysis. Mutat. Res. 549 (2004) 29-41
14. Hu T., Gibson D.P., Carr G.J., Torontali S.M., Tiesman J.P., Chaney J.G., and Aardema M.J. Identification of a gene expression profile that discriminates indirect-acting genotoxins from direct-acting genotoxins. Mutat. Res. 549 (2004) 5-27
15. van Delft J.H., van A.E., van Breda S.G., Herwijnen M.H., Staal Y.C., and Kleinjans J.C. Discrimination of genotoxic from non-genotoxic carcinogens by gene expression profiling. Carcinogenesis 25 (2004) 1265-1276
16. Liber H.L., and Thilly W.G. Mutation assay at the thymidine kinase locus in diploid human lymphoblasts. Mutat. Res. 94 (1982) 467-485
17. Zhang L.S., Honma M., Hayashi M., Suzuki T., Matsuoka A., and Sofuni T. A comparative study of TK6 human lymphoblastoid and L5178Y mouse lymphoma cell lines in the in vitro micronucleus test. Mutat. Res. 347 (1995) 105-115
18. Johnson D.G., and Walker C.L. Cyclins and cell cycle checkpoints. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 295-312
19. Lobert S., Vulevic B., and Correia J.J. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry 35 (1996) 6806-6814
20. Mullins D.W., Burger C.J., and Elgert K.D. Tumor growth modulates macrophage nitric oxide production following paclitaxel administration. Int. J. Immunopharmacol. 20 (1998) 537-551
21. Lehmann M., Vilar K.S., Franco A., Reguly M.L., and Rodrigues de Andrade H.H. Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the drosophila somatic mutation and recombination test. Environ. Mol. Mutagen. 43 (2004) 250-257
22. Ferguson L.R., Whiteside G., Holdaway K.M., and Baguley B.C. Application of fluorescence in situ hybridisation to study the relationship between cytotoxicity, chromosome aberrations, and changes in chromosome number after treatment with the topoisomerase II inhibitor amsacrine. Environ. Mol. Mutagen. 27 (1996) 255-262
23. Hande K.R. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer 34 (1998) 1514-1521
24. Takimoto C.H., Wright J., and Arbuck S.G. Clinical applications of the camptothecins. Biochim. Biophys. Acta 1400 (1998) 107-119
25. Budzik G.P., Colletti L.M., and Faltynek C.R. Effects of methotrexate on nucleotide pools in normal human T cells and the CEM T cell line. Life Sci. 66 (2000) 2297-2307
26. McLeod H.L., Sludden J., Hardy S.C., Lock R.E., Hawksworth G.M., and Cassidy J. Autoregulation of 5-fluorouracil metabolism. Eur. J. Cancer 34 (1998) 1623-1627
27. Spasokoukotskaja T., Sasvari-Szekely M., Keszler G., Albertioni F., Eriksson S., and Staub M. Treatment of normal and malignant cells with nucleoside analogues and etoposide enhances deoxycytidine kinase activity. Eur. J. Cancer 35 (1999) 1862-1867
28. Hendricks S.P., and Mathews C.K. Differential effects of hydroxyurea upon deoxyribonucleoside triphosphate pools, analyzed with vaccinia virus ribonucleotide reductase. J. Biol. Chem. 273 (1998) 29519-29523
29. Lemoine A., Lucas C., and Ings R.M. Metabolism of the chloroethylnitrosoureas. Xenobiotica 21 (1991) 775-791
30. Neault J.F., and Tajmir-Riahi H.A. Interaction of cisplatin with human serum albumin. Drug binding mode and protein secondary structure. Biochim. Biophys. Acta 1384 (1998) 153-159
31. Seidel S.D., Kan H.L., Stott W.T., Schisler M.R., and Gollapudi B.B. Identification of transcriptome profiles for the DNA-damaging agents bleomycin and hydrogen peroxide in L5178Y mouse lymphoma cells. Environ. Mol. Mutagen. 42 (2003) 19-25
32. Amundson S.A., Myers T.G., and Fornace Jr. A.J. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 17 (1998) 3287-3299
33. Seo Y.R., and Jung H.J. The potential roles of p53 tumor suppressor in nucleotide excision repair (NER) and base excision repair (BER). Exp. Mol. Med. 36 (2004) 505-509
34. Muller A., Boitier E., Hu T., Carr G.J., Le Fevre A.C., Marchandeau J.P., Flor M., Jefferson F., Aardema M.J., and Thybaud V. Laboratory variability does not preclude identification of biological functions impacted by hydroxyurea. Environ. Mol. Mutagen. 46 (2005) 221-235
35. Islaih M., Halstead B.W., Kadura I.A., Li B., Reid-Hubbard J.L., Flick L., Altizer J.L., Thom D.J., Monteith D.K., Newton R.K., and Watson D.E. Relationships between genomic, cell cycle, and mutagenic responses of TK6 cells exposed to DNA damaging chemicals. Mutat. Res. 578 (2005) 100-116
36. Zhu C., and Jiang W. Cell cycle-dependent translocation of PRC1 on the spindle by Kif4 is essential for midzone formation and cytokinesis. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 343-348
37. Kurasawa Y., Earnshaw W.C., Mochizuki Y., Dohmae N., and Todokoro K. Essential roles of KIF4 and its binding partner PRC1 in organized central spindle midzone formation. EMBO J. 23 (2004) 3237-3248
38. Bischoff J.R., and Plowman G.D. The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis. Trends Cell Biol. 9 (1999) 454-459
39. Ewart-Toland A., Briassouli P., de Koning J.P., Mao J.H., Yuan J., Chan F., Carthy-Morrogh L., Ponder B.A., Nagase H., Burn J., Ball S., Almeida M., Linardopoulos S., and Balmain A. Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat. Genet. 34 (2003) 403-412
40. Fletcher J., and Starr R. The role of suppressors of cytokine signalling in thymopoiesis and T cell activation. Int. J. Biochem. Cell Biol. 37 (2005) 1774-1786
41. Inamura K., Matsuzaki Y., Uematsu N., Honda A., Tanaka N., and Uchida K. Rapid inhibition of MAPK signaling and anti-proliferation effect via JAK/STAT signaling by interferon-alpha in hepatocellular carcinoma cell lines. Biochim. Biophys. Acta 1745 (2005) 401-410
42. Tanaka N., Kamanaka M., Enslen H., Dong C., Wysk M., Davis R.J., and Flavell R.A. Differential involvement of p38 mitogen-activated protein kinase kinases MKK3 and MKK6 in T-cell apoptosis. EMBO Rep. 3 (2002) 785-791
43. Ichijo H., Nishida E., Irie K., ten D.P., Saitoh M., Moriguchi T., Takagi M., Matsumoto K., Miyazono K., and Gotoh Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275 (1997) 90-94
44. bou-Rjaily G.A., Lee S.J., May D., Al-Share Q.Y., Deangelis A.M., Ruch R.J., Neumaier M., Kalthoff H., Lin S.H., and Najjar S.M. CEACAM1 modulates epidermal growth factor receptor-mediated cell proliferation. J. Clin. Invest. 114 (2004) 944-952
45. Khan A.A., Bose C., Yam L.S., Soloski M.J., and Rupp F. Physiological regulation of the immunological synapse by agrin. Science 292 (2001) 1681-1686
46. Wang Q., Xie S., Chen J., Fukasawa K., Naik U., Traganos F., Darzynkiewicz Z., Jhanwar-Uniyal M., and Dai W. Cell cycle arrest and apoptosis induced by human Polo-like kinase 3 is mediated through perturbation of microtubule integrity. Mol. Cell Biol. 22 (2002) 3450-3459
47. Richardson H.E., Stueland C.S., Thomas J., Russell P., and Reed S.I. Human cDNAs encoding homologs of the small p34Cdc28/Cdc2-associated protein of Saccharomyces cerevisiae and Schizosaccharomyces pombe. Genes Dev. 4 (1990) 1332-1344
48. DeSalle L.M., and Pagano M. Regulation of the G1 to S transition by the ubiquitin pathway. FEBS Lett. 490 (2001) 179-189
49. Rape M., and Kirschner M.W. Autonomous regulation of the anaphase-promoting complex couples mitosis to S-phase entry. Nature 432 (2004) 588-595
50. Gassmann R., Carvalho A., Henzing A.J., Ruchaud S., Hudson D.F., Honda R., Nigg E.A., Gerloff D.L., and Earnshaw W.C. Borealin: a novel chromosomal passenger required for stability of the bipolar mitotic spindle. J. Cell Biol. 166 (2004) 179-191